Avenge Bio is a Natick, MA-based oncology biotechnology company developing cell-based immunotherapeutic products using its LOCOcyte™ platform. The platform delivers proprietary engineered cells to the local tumor environment to generate high concentrations of immune effector molecules near tumors, initiating a local and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Its lead candidate, AVB-001, produces native IL-2 immunotherapy and is being developed initially for metastatic peritoneal cancers, with a primary focus on recurrent and refractory ovarian cancer. The company also has additional pipeline candidates targeting pancreatic, lung and breast cancers. Avenge Bio closed a $45M Series A financing in October 2022. Proceeds will advance AVB-001 through an IND filing and into the clinic and support continued rapid development of the pipeline.

Total raised

$45M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2022